1-6 of 6
Anna Franklin
Close
Sort by
Journal Articles

Brentuximab Vedotin As Consolidation Therapy Following Autologous Stem Cell Transplantation in Children and Adolescents with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Center Retrospective Analysis

Christopher J. Forlenza, Jaclyn Rosenzweig, Audrey Mauguen, Ilia Buhtoiarov, Branko Cuglievan, Hema Dave, Rebecca J Deyell, Jaime Flerlage, Anna Franklin, Jennifer Krajewski, Kasey J Leger, Lianna Marks, Robin Norris, Martha Pacheco, Faye Willen, Adam Paul Yan, Paul Harker-Murray, Lisa Giulino Roth
Journal: Blood
Blood (2021) 138 (Supplement 1): 2465.
https://doi.org/10.1182/blood-2021-151808
Published: 2021
Journal Articles

Brentuximab Vedotin Plus Bendamustine for Pediatric Patients with Relapsed/Refractory Hodgkin Lymphoma: A Multi-Institution Retrospective Analysis

Christopher J. Forlenza, MD, Nitya Gulati, MBBS, Audrey Mauguen, PhD, Michael J. Absalon, Sharon M. Castellino, MD MSc, Anna Franklin, MD, Frank G. Keller, MD, Neal Shukla, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35.
https://doi.org/10.1182/blood-2020-139480
Published: 2020
Journal Articles

Phase 1 Results from a Phase 1/2 Study to Assess the Safety, Tolerability and Recommended Phase 2 Dose (RP2D) of Brentuximab Vedotin Plus Doxorubicin, Vinblastine and Dacarbazine (A+AVD) in Pediatric Patients (Pts) with Advanced Stage Newly Diagnosed Classical Hodgkin Lymphoma (cHL)

Anna Franklin, MD, Marco Zecca, MD, Franca Fagioli, MD, Flavio Augusto Luisi, Gregory Song, Ajit Suri, E. Jane Leonard, Franco Locatelli
Journal: Blood
Blood (2018) 132 (Supplement 1): 1644.
https://doi.org/10.1182/blood-2018-99-112488
Published: 2018
Journal Articles

Adolescent and Young Adult Patients Treated with Modified Augmented Berlin-Frankfurt-Muenster Therapy

Michael E. Rytting, MD, Hagop M. Kantarjian, MD, Deborah A Thomas, MD, Elias Jabbour, MD, Anna Franklin, M.D., Farhad Ravandi, MD, Stefan Faderl, MD, Rebecca Garris, BA, Tapan Kadia, MD, Kurt Schroeder, RN, Susan O'Brien, MD
Journal: Blood
Blood (2010) 116 (21): 3250.
https://doi.org/10.1182/blood.V116.21.3250.3250
Published: 2010
Journal Articles

Outcome for Adolescents and Young Adults (AYA) with the Hyper-CVAD (with or without Rituximab) Regimens for De Novo Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma.

Deborah A. Thomas, MD, Michael Rytting, M.D., Susan O'Brien, MD, Stefan Faderl, MD, William G. Wierda, MD, PhD, Anna Franklin, MD, Rebecca Garris, Farhad Ravandi, MD, Jorge Cortes, MD, Hagop M. Kantarjian, MD
Journal: Blood
Blood (2009) 114 (22): 3084.
https://doi.org/10.1182/blood.V114.22.3084.3084
Published: 2009
Journal Articles

Young Adults with Acute Lymphoblastic Leukemia (ALL) Treated with Adapted Augmented Berlin-Frankfurt-Munster (ABFM) Therapy

Michael Rytting, M.D., Deborah Thomas, M.D., Anna Franklin, M.D., William Wierda, M.D., Stefan Faderl, M.D., Farhad Ravandi, M.D., Brenda Muriera, RN, Hagop M. Kantarjian, MD, Susan O’Brien, M.D.
Journal: Blood
Blood (2008) 112 (11): 3957.
https://doi.org/10.1182/blood.V112.11.3957.3957
Published: 2008